Skip to content Skip to footer

European Court of Justice Rules that CBD is not a narcotic

European Court of Justice Rules that CBD is not a narcotic
Share this story

November 19th, 2020

Conor O’Brien, George Brown


 

The European Court of Justice (ECJ) ruled this morning on a pivotal case involving the legality of CBD within the EU. The case involves defendants Kanavape who have been under prosecution in France for importing CBD to be marketed in vaporiser cartridges. The five judges on the ECJ were to rule whether an EU state can place a ban on the marketing of a CBD product which is legally produced in another state. This case rested on whether CBD is considered a narcotic under EU law, as determined by interpretation of the UN Single Convention on Narcotic Substances.

The ECJ ruled this morning that CBD should not be considered a narcotic under the 1961 UN Convention, as CBD does not “have any psychotropic effect or any harmful effect on human health”. The Court said that while CBD could technically have been included in the legislation set out in the UN convention, banning CBD would be “contrary to the general spirit of that convention and to its objective of protecting ‘the health and welfare of mankind’”. Furthermore, the court ruled that EU states cannot ban the marketing of CBD legally produced in another member state unless a risk to public health “appears sufficiently established”.

This ruling will have large scale implications for CBD in Europe and further abroad. Within the EU, it is now likely that all nations will accept the marketing of CBD produced not only from seeds and stalks but from leaves and flowers, as is the case with the products of Kanavape. More than 50 companies who are applying to register their products as Novel Foods within the EU will now be able to resume this process which would eventually allow marketing of their CBD food substances. The court’s decision may also influence the position of the EU states at the upcoming UN vote in December on the classification of cannabis in international law. The EU had previously leaned against declassifying CBD under international law but now may well support the motion which could potentially sway the outcome.

Read the full ruling, here.

To join the conversation on CBD, cannabis and psychedelics in Europe and Globally, see the Prohibition Partners Live conference running from 17th-20th of November 2020. To celebrate the court ruling, a 40% discount on tickets is being offered via the code EUCBD40.

Enjoy access to the full panel discussion: It’s Not EU, It’s Me: The European Cannabis Puzzle

 For more in-depth information, market data and strategic support, contact the Prohibition Partners consultancy team at info@prohibitionpartners.com or download one of our industry-leading reports.

Recent posts
October 16, 2024
Medical Cannabis Sales in Germany Expected to Reach €420 Million in 2024
January 31, 2024
New Reforms Set to Send Israeli Medical Cannabis Patient Numbers Soaring – Industry Growth to Follow
January 31, 2024
LAUNCHING TODAY | The Israeli Cannabis Report
January 23, 2024
LAUNCHING TODAY | Oceania Regulatory Report

Catch up on our newest articles that you might have missed

WEB_slider-German-report-02
October 16, 2024
Medical Cannabis Sales in Germany Expected to Reach €420 Million in 2024
Following the adoption of the CanG and the associated MedCanG Act, the German medical cannabis market is witnessing significant growth,...
israel cannabis reform
January 31, 2024
New Reforms Set to Send Israeli Medical Cannabis Patient Numbers Soaring – Industry Growth to Follow
The number of Israeli patients using medical cannabis is set to soar by 2027, as imminent reforms will make it...
Israel cannabis
January 31, 2024
LAUNCHING TODAY | The Israeli Cannabis Report
Prohibition Partners are proud to announce the publication of The Israeli Cannabis Report.  This report delves into the intricate journey...
WEB_slider-Oceania-report_2
January 23, 2024
LAUNCHING TODAY | Oceania Regulatory Report
Prohibition Partners are proud to announce the publication of the Oceania Regulatory Report today. This report provides a current regulatory...

Market Briefing Request

Please complete your details and a representative will be in contact

In Depth Analysis Session Request

Please complete your details and a representative will be in contact

Data Access Request

Please complete your details and a representative will be in contact